Next Article in Journal
Cybernetic Principles in Psychophysiology: Their Significance and Conclusions for Palliative Care
Previous Article in Journal
Successful Intraosseous (IO) Adenosine Administration for the Termination of Supraventricular Tachycardia (SVT) in a 3.5-Year-Old Child—Case Report and Literature Review
Previous Article in Special Issue
Quantitative Evaluation of Dental Students’ Perceptions of the Roleplay-Video Teaching Modality in Clinical Courses of Dentistry: A Pilot Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Computer Simulation of Catheter Cryoablation for Pulmonary Vein Isolation

by
Solange I. Rivera
1,
Clara P. Bernal
2,
Rafael Martínez-Peláez
3,4,
Rogelio Robledo-Nolasco
5,
Gerardo De León-Larios
5,
Vanessa G. Félix
4,
Rodolfo Ostos
4,
Gladys E. Maestre
6,
Jesús D. Melgarejo
6 and
Luis J. Mena
4,*
1
Department of Chemical, Electronic and Biomedical Engineering, Science and Engineering Division, Universidad de Guanajuato, Guanajuato 36250, Mexico
2
Faculty of Engineering and Technologies, Universidad La Salle Bajío, Leon 36700, Mexico
3
Department of Systems and Computer Engineering, Faculty of Engineering and Geological Sciences, Universidad Católica del Norte, Antofagasta 1270709, Chile
4
Computer Academic Unit, School of Information Technologies, Universidad Politécnica de Sinaloa, Mazatlan 82199, Mexico
5
Department of Interventional Cardiology and Electrophysiology, Centro Médico Nacional 20 de Noviembre ISSSTE, Mexico City 03100, Mexico
6
Institute of Neuroscience, School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78550, USA
*
Author to whom correspondence should be addressed.
Healthcare 2024, 12(15), 1508; https://doi.org/10.3390/healthcare12151508
Submission received: 11 June 2024 / Revised: 8 July 2024 / Accepted: 15 July 2024 / Published: 30 July 2024
(This article belongs to the Collection Clinical Simulation in Health Sciences)

Abstract

:
Cryoablation is a well-established medical procedure for surgically treating atrial fibrillation. Cryothermal catheter therapy induces cellular necrosis by freezing the insides of pulmonary veins, with the goal of disrupting abnormal electrical heart signals. Nevertheless, tissue damage induced by cold temperatures may also lead to other complications after cardiac surgery. In this sense, the simulation of catheter ablation can provide safer environments for training and the performance of cryotherapy interventions. Therefore, in this paper, we propose a novel approach to help better understand how temperature rates can affect this procedure by using computer tools to develop a simulation framework to predict lesion size and determine optimal temperature conditions for reducing the risk of major complications. The results showed that a temperature profile of around −40 °C caused less penetration, reduced necrotic damage, and smaller lesion size in the tissue. Instead, cryotherapy close to −60 °C achieved a greater depth of temperature flow inside the tissue and a larger cross-section area of the lesion. With further development and validation, the framework could represent a cost-effective strategy for providing personalized modeling, better planning of cryocatheter-based treatment, and preventing surgical complications.

1. Introduction

In recent decades, emerging computer technologies have played a critical role in modern medicine and life sciences [1]. Computer solutions based on the integration of machine learning, mobile computing, and modeling have provided a more complete approach to healthcare. This has improved the accuracy and effectiveness of prevention, diagnosis, and treatment strategies for chronic disorders [2,3,4].
In cardiovascular science, computational models and monitoring mobile systems have been developed to design patient-specific modeling for cardiac surgery [5] and to record cardiovascular health data at anytime and anywhere [6]. Moreover, computed tomography scans and magnetic resonance imaging have provided a more detailed assessment of the heart [7], and image-guided interventions provide real-time information to conduct more precise and safer cardiac procedures [8].
On the other hand, computer simulations have also been used to improve clinical practice in low-resource settings [9]. The development of simulated environments has contributed to improving the quality of cardiology training programs [10,11], increasing the effectiveness of therapy [12], reducing risks for patients [13], and enhancing the performance of surgical interventions [14]. For the assessment and surgical treatment of heart-valve disease, patient-specific computer simulation may improve the planning and results of catheter-based treatment [15,16].
Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia, affecting an estimated 33.5 million people worldwide [17]. The disease is more prevalent among older adults [18] and it is one of the leading causes of stroke, sudden death, and cardiovascular morbidity and mortality in the world [19]. AF is a supraventricular tachycardia characterized by disorganized atrial activation and consequent impairment of atrial mechanical function, with focal origins in the pulmonary veins (PVs) [20]. Over the past 20 years, the rates of individuals with AF and hospitalizations attributed to AF have been increasing; this is probably due to the fast aging of the population [21]. In Mexico, studies have reported an increased risk of cerebral and systemic embolism attributed to AF [22], as well as in the incidence of the disease in the population [23].
The treatment for AF aims at controlling sinus rhythm and heartrate rhythms [24], which are initially achieved with the use of an oral anticoagulant and antiarrhythmic drugs [25]. However, in addition to monitoring the side effects of these medications [24,26], complete elimination of persistent AF is frequently unsuccessful with only oral pharmacological agents [24]. Therefore, catheter ablation therapy has emerged as the most effective alternative for surgically treating AF [26,27]. This medical procedure uses thermal energies to create small scars inside the PVs, disrupting the electrical signals that cause AF. Radiofrequency (RF) and cryothermal are the most widely used energy sources for performing cardiac ablation [27,28,29,30]. Despite RF being considered a gold standard method [26,27], RF ablation converts electromagnetic energy to thermal energy [31], which results in the heating and destruction of tissue [32]. In addition, the size of tissue damaged correlates with the amount and duration of the energy delivered to produce heat on the tissue [31,32]. Thus, high power and larger time periods of RF ablation have been associated with cardiac perforations [33], pericardial effusion/tamponade [34], and PV stenosis [35].
PV isolation achieved by cryoablation (CBA) has similar effectiveness to RF for treating AF as it is a shorter procedure and has lower rates of major complications [26,27,30,36]. In CBA, cryothermal energy applied with a balloon leads to cellular necrosis by freezing the target region [37,38,39]. CBA is now considered a well-established and safe treatment option to perform circumferential isolation of the PVs [27,40]. The most common complication associated with CBA is phrenic nerve palsy [27,41,42], which can be avoided by reducing the total freezing time [43], implementing compound motor action potential monitoring [44], or immediate balloon deflation [45]. To avoid such complications, computerized simulations can provide safer CBA environments for reducing surgical complications and preventing irreversible damage to the atrium or PVs [45,46]. Some computer models have been developed to improve the knowledge of the biophysics behind AF ablation [47]. These computerized models have evaluated how heterogeneous ventricular tissues influence lesion size [48], how blood motion affects the cardiac chamber [49], how tissue surface can be modeled based on data generated by the RF ablation [50], and how to represent different electrode–tissue contact force values [51].
For CBA therapies, a computer cryoballoon model has been proposed that uses electromagnetic and thermal simulations to estimate the temperature profile that may be used to optimize AF ablation [52,53]. Nevertheless, no specific criteria have been established to select an appropriate temperature rate during the CBA procedure. Some computational models have predicted a minimum duration of freezing to obtain a durable and transmural lesion of cardiac tissue [54]. In addition, other parameters, such as cryoballoon position, seem to also affect the predicted effectiveness of the procedures [55]. To the best of our knowledge, there is not a computer-model study that addresses the estimation of an adequate temperature profile for CBA, based on lesion simulation in cardiac tissue. Therefore, in this paper, we proposed a novel simulation framework approach to (1) help better understand how temperature rates can affect CBA procedure; (2) represent adequate lesion size; (3) guide better CBA dosing strategies; and (4) determine optimal temperature conditions for reducing the risk of major complications.

2. Materials and Methods

2.1. Software

For modeling and simulation of the CBA procedure, we used COMSOL Multiphysics software (v5.4), which is a general-purpose simulation software that provides a user-friendly environment to analyze a wide range of physical phenomena [54] including CBA treatments [53]. The Heat Transfer module [54] was used to model operational conditions during freezing and thawing phases. This tool includes a library for bioheating applications [54] that allows accounting for the influence of various processes in living tissue as contributions of heat exchange between a structure and its surroundings (heat flow) and flow direction of heat per unit of area (heat flux). Laminar flow interface [54] was also used to compute specific physical parameters of blood fluid in PVs, such as dynamic viscosity, flow pressure, and velocity.

2.2. Simulation Parameters

Computer simulations were performed for four materials according to the thermal and physiological properties described in Table 1. Mean body temperature of 36.7 °C [56], and volumetric blood perfusion of 0.012 mL s−1 cm−3 [57], were predefined. In addition, a heat flux of −151,924.04 joules was applied toward the polyurethane balloon equivalent to minimal internal temperature fixed at −80 °C [58]. Metabolic heat generation for solid material (polyurethane) was not considered in the simulation because specified solids are homogeneous and cause blood perfusion but no significant metabolic activity [59].
Temperature response of biological tissue due to the heat conduction in PVs by blood perfusion was modeled using the Pennes bioheat transfer equation [60], because lesion size is affected by the intramyocardial blood flow [61]. Thus, this equation is widely used to solve the temperature distribution between tissue and blood for thermal therapies [62]:
ρ c   T / t =   ( k   T ) + W b   C b   ( T a T ) + Q m
where ρ is tissue density, c is specific heat, k is thermal conductivity, Cb is the specific heat of blood, Ta is arterial blood temperature, T is ambient temperature, ∂T/∂t is the rate of temperature variation, Wb is the blood flow velocity per unit volume, and Qm is metabolic heat generation. Equation (1) was applied for each of the materials used in the implementation of the three-dimensional model, with the parameters shown in Table 1.

2.3. Dataset

Data to estimate thermal conductivity (k) for different PVs were collected from therapy logs of five patients (mean age 55.7 years; 60% women) of the hemodynamics unit of Centro Medico Nacional 20 de Noviembre in Mexico City. Informed consent was obtained for all subjects. The ethical review board of Centro Medico Nacional 20 de Noviembre approved the protocol.
Table 2 shows time (seconds) and temperature records of patients undergoing CBA therapy for isolation of the PVs. TZ is the time when the thermocouple indicated a temperature of zero degrees Celsius (°C), TI is the time when it reached −30 °C, TM is the time when the cryoballoon reached the maximum cold temperature (time to isolation) in each specific CBA procedure, and TT is the total time of cryotherapy, including when the tissue returned to its initial temperature after the thawing phase.

2.4. Simulation Model

For designing and developing the simulation models, we specifically used the COMSOL Multiphysics module of Heat Transfer in Solids (ht) [54], with the aim of modeling tissue cooling based on convection heat exchange between solid synthetic material (polyurethane of cryoballoon) and solid biological tissue (vascular wall of PV). The geometry of the computational model consisted of three concentric cylinders with a height of 60 mm. The innermost cylinder replicated the vascular lumen of PVs, a hollow passageway through which blood flows [63]; the second cylinder simulated pulmonary tissue; and the outermost cylinder represented the vascular wall pulmonary tissue in contact with the exterior. The first cylinder (Figure 1) included an ellipsoid with diameters of 23 mm and height of 20 mm to approximately represent second-generation cryoballoon Medtronic Arctic Front Advance, with an inflated balloon diameter of 23 mm [64].
Using previous normal values established for diameter and thickness of PVs [65,66], we calculated the average value to define simulation parameters for each PV (Table 3).
Simulation was performed by each patient with a balloon inflated to 23 mm. Two freezing/thawing cycles were administered in each case to ensure representation of effective therapy. Depth of temperature flow was used to measure changes and penetration of cold through tissue, for estimating lesion formation size as temperature increases during CBA treatment.

2.5. Estimation of Lesion

For representing thermal lesion cross-section area during the CBA procedure, we proposed Equation (2); using the ellipse area formula by considering lesion morphology as an elliptical shape [51] (see Figure 2); estimating lesion depth (A) by multiplying by 2 the highest distance between cryoballoon and the outermost border of pulmonary tissue; and defining lesion width (B) as a constant of 23 mm according to the diameter of the inflated balloon. This takes into account the zone of cooling around the equator of the second-generation cryoballoon extended, producing more uniform lesions independent of the position of the balloon [67].
L e s i o n   A r e a = π × 2 A 2 × B 2                
where A is lesion depth and B is lesion width.

2.6. Temperature Parameters

Conversion of Kelvin to Celsius temperature was calculated by subtracting 273.15 from the Kelvin temperature. Temperature cooler than −15 °C was considered the limit to start measuring the depth and width of the lesion, because ice crystals form exclusively in the extracellular space as the tissue temperature drops below this threshold [38].

3. Results

3.1. Temperature Distribution

Three-dimensional computational model tracked changes in temperature over time during CBA is illustrated in Figure 2. The temperature distribution is represented using a color scale. Each different color line indicates temperature changes in the target region. The green color corresponds to a temperature of 0 °C, which will be used to determine the lesion tissue boundary. Our results demonstrate that temperature was evenly distributed in the model during the first 10 s of each therapy. The direction of the heat flow was reflected negatively since the cryocatheter acted as a heat absorber inside the tissue. Heat flow moved from the hotter to colder areas as it approached the cryoballoon. A heat flow of −7.84 joules was observed during the simulation for predefined values, with an internal cryoballoon temperature of −80 °C, tissue temperature of 36.7 °C, and heat flux of −151,924.04 joules.

3.2. CBA Simulation

During the simulation of tissue freezing for five patients undergoing cryotherapy (Figure 3), the temperature distribution on the front face of the geometric model was nonuniform after 240 s. Most therapies reached 0 °C after the initial 10 s of localized cooling, resulting in tissue damage on the contact area with the cryoballoon and at the periphery due to hypothermia. Maximum freezing temperatures for PV isolation were reached in an average time of 35.20 ± 3.54 s.
The model also monitored the moment when the thermocouple registered −30 °C, because this temperature usually results in vasoconstriction as an initial response of the cells to the application of ice [68]. It is important to note that at temperatures between 0 °C and −15 °C, the majority of cells exhibit unique resistivity to freezing for short periods because the cell membrane acts as a barrier to ice crystal nucleation [69]. Therefore, ice crystal formation began in the extracellular space at −15 °C (heterogeneous nucleation) [38], creating initial tissue damage. As the temperature dropped between −20 °C and −30 °C, vascular equilibrium was reached and ice crystal formation in the intracellular space was observed, resulting in increased tissue injury. This situation occurred because the ice crystals compressed and deformed the nucleus, and cytoplasmic components led to permanent cellular dysfunction. On the other hand, for cryogenic therapy close to −40 °C, the formation of clusters of ice crystals was observed inside and outside the cell (homogeneous nucleation) [69]. This phenomenon resulted in irreversible disruption of organelles and the cell membrane, and led to cell death through apoptosis.
Finally, we show, in Figure 4 and Table 4, relevant measurements of each patient corresponding to lesion size and temperature flow inside tissue after cryotherapy. Higher distances between the cryoballoon and the vascular wall indicated a lower value of temperature flow depth and, therefore, less penetration of cryothermal energy into the tissue. The average of lesion depth predictions for simulated ablation was 3.51 ± 0.51 mm, which is in agreement with previous in vivo performance studies of the second-generation cryoballoon (3.02 ± 1.13 mm) [70].

4. Discussion

This study generated simulations of thermal propagation by freeze application inside tissue during cryotherapy. This method allowed us to assess the effectiveness of CBA procedures based on lesion formation size, temperature changes through tissue depths, and reduction in surgical complications. The simulation framework provided a basic approach to geometrically model lesions inside PVs by tracking thermodynamic changes over time and estimating tissue injury as a response to freezing on contact with tissue at 36 °C. Computer simulation incorporated the Pennes bioheat equation to model the effect of heat transfer by blood perfusion in PVs while the tissue is in a nonfrozen state. Additionally, relevant time and temperature conditions of real clinical practice of CBA were also added to the model.
After analyzing the model predictions in relation to tissue damage with respect to vascular wall temperature after 240 s of therapy, our simulations indicated that at approximately −40 °C there was lower penetration of temperature into tissue. This resulted in less lesion depth, reduced necrotic tissue, and smaller lesion size. On the other hand, in the case of temperatures close to −60 °C and higher profundity of temperature flow inside the tissue, the simulations indicated a larger depth of the lesion. Overall, CBA procedures were considered successful because the formation of cluster-like ice crystals was also evident for this temperature range.
Our simulations also indicated that a temperature profile around −40 °C could enhance cellular self-support against crystal formation, allowing greater effectiveness in cryogenic therapy because ice crystal formation by extreme freezing (temperature colder than −50 °C) can cause abrasive action on the tissue, mechanically disrupting cardiac cells, and ultimately leading irreversible tissue damage [38,71]. On the other hand, this temperature profile could help to reduce phrenic nerve injury occurring at lower temperature rates (mean −49.5 °C; median −50 °C) [72] as the phrenic nerve temperature is strongly associated with the durability of phrenic nerve damage [73].
Based on our work, we propose a novel computer framework to predict CBA lesions from real patient data and better guide future studies for dosing cryoenergy transfer by using progressive cooling from −30 °C (intracellular ice crystal formation) to below –50 °C (permanent tissue damage). Favorable outcomes in CBA procedures based on computational simulations may improve the safe planning of CBA treatments and optimize costs by performing in vivo clinical trials [74]. To the best of our knowledge, this is the first CBA computational model that adequately represents lesion size, estimates an appropriate temperature profile to reduce clinical complications, proposes a temperature range for a better dosing strategy of freezing, and uses multiple data from patients with informed consent.

Limitations

Our study should be interpreted within the context of its limitations. First, this study included a small data sample due to the difficulty of obtaining informed consent, derived from limited health literacy [75] and a low level of comprehension of our study population about the informed consent process [76]. Nevertheless, previous CBA simulation studies do not report evidence of real data [52,53]. On the other hand, analytical predictive studies may provide more truthful results with a small sample, because modeling parameters can be controlled with higher precision [77]. Second, regarding the construction of our models and simulations, geometric modeling included perfectly concentric cylinders and ellipsoids to represent PVs and the cryoballoon. Moreover, simulation parameters for heat transfer during vascular perfusion were defined by assuming homogeneous tissues and suitable balloon positioning. Therefore, although these assumptions contributed to addressing model complexity, these could decrease the precision of simulating interactions among ice crystal formation, blood flow, and heat transfer on cardiac tissue, and subsequently predict lesion formation during the CBA procedure. Furthermore, modeling was performed with a second-generation cryoballoon (Arctic Front Advance). A fourth-generation design (Arctic Front Advance Pro) is currently available with significant improvements in cold transfer that capture temperatures and time-to-isolation monitoring [53,78]. This is a dilemma every model faces to achieve an appropriate balance between accuracy and simplicity [79].

5. Conclusions

We developed a computer simulation framework to estimate the optimal temperature profile according to CBA lesion formations. The model confirmed that the efficacy of the procedure is sensitive to freeze rates. Our findings indicate that temperatures around −40 °C could reduce collateral damage and irreversible cardiac tissue injury. With further development and validation, the framework could represent a cost-effective strategy for providing personalized modeling for CBA, better planning of cryocatheter-based treatment, and prevention of major surgical complications.

Author Contributions

Conceptualization: S.I.R., C.P.B., R.R.-N. and G.D.L.-L.; methodology: S.I.R. and R.M.-P.; software: S.I.R.; validation: R.R.-N. and G.D.L.-L.; formal analysis: R.M.-P. and L.J.M.; investigation, V.G.F., R.O. and J.D.M.; data curation, L.J.M. and J.D.M.; writing—original draft preparation; S.I.R. and L.J.M.; writing—review and editing: L.J.M. and J.D.M.; visualization: V.G.F. and R.O.; supervision: G.E.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Centro Medico Nacional 20 de Noviembre (Approval Code: 2730 on 11 February 2013).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Acknowledgments

We acknowledge the hemodynamic unit of Centro Médico Nacional 20 de Noviembre for supporting the preparation and development of this work. All authors have consented to the acknowledgements.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Whig, P.; Velu, A.; Nadikattu, R.R.; Alkali, Y.J. Computational science role in medical and healthcare-related approach. In Handbook of Computational Sciences: A Multi and Interdisciplinary Approach; Elgnar, A.A., Vigneshwar, M., Singh, K.K., Polkowski, Z., Eds.; Wiley: Hoboken, NJ, USA, 2023; pp. 245–272. [Google Scholar]
  2. Krishnamoorthy, S.; Dua, A.; Gupta, S. Role of emerging technologies in future IoT-driven Healthcare 4.0 technologies: A survey, current challenges and future directions. J. Ambient. Intell. Humaniz. Comput. 2023, 14, 361–407. [Google Scholar] [CrossRef]
  3. Baladron, C.; de Diego, J.J.G.; Amat-Santos, I.J. Big data and new information technology: What cardiologists need to know. Rev. Esp. Cardiol. 2021, 74, 81–89. [Google Scholar] [CrossRef] [PubMed]
  4. Mena, L.J.; Félix, V.G.; Ostos, R.; González, A.J.; Martínez-Peláez, R.; Melgarejo, J.D.; Maestre, G.E. Mobile personal health care system for noninvasive, pervasive, and continuous blood pressure monitoring: Development and usability study. JMIR mHealth uHealth 2020, 8, e18012. [Google Scholar] [CrossRef] [PubMed]
  5. del Álamo, J.C.; Marsden, A.L.; Lasheras, J.C. Avances en mecánica computacional para el diagnóstico y tratamiento de la enfermedad cardiovascular. Rev. Esp. Cardiol. 2009, 62, 781–805. [Google Scholar] [CrossRef] [PubMed]
  6. Mena, L.J.; Félix, V.G.; Ochoa, A.; Ostos, R.; González, E.; Aspuru, J.; Velarde, P.; Maestre, G.E. Mobile personal health monitoring for automated classification of electrocardiogram signals in elderly. Comput. Math. Methods Med. 2018, 2018, 9128054. [Google Scholar] [CrossRef] [PubMed]
  7. Kwong, R.Y.; Yucel, E.K. Computed tomography scan and magnetic resonance imaging. Circulation 2003, 108, e104–e106. [Google Scholar] [CrossRef] [PubMed]
  8. Cleary, K.; Peters, T.M. Image-guided interventions: Technology review and clinical applications. Annu. Rev. Biomed. Eng. 2010, 12, 119–142. [Google Scholar] [CrossRef] [PubMed]
  9. Salifu, D.A.; Heymans, Y.; Christmals, C.D. A simulation-based clinical nursing education framework for a low-resource setting: A multimethod study. Healthcare 2022, 10, 1639. [Google Scholar] [CrossRef] [PubMed]
  10. Chaer, R.A.; DeRubertis, B.G.; Lin, S.C.; Bush, H.L.; Karwowski, J.K.; Birk, D.; Morrissey, N.J.; Faries, P.L.; McKinsey, J.F.; Kent, K.C. Simulation improves resident performance in catheter-based intervention: Results of a randomized, controlled study. Ann. Surg. 2006, 244, 343–352. [Google Scholar] [CrossRef]
  11. Westerdahl, D.E. The necessity of high-fidelity simulation in cardiology training programs. J. Am. Coll. Cardiol. 2016, 67, 1375–1378. [Google Scholar] [CrossRef]
  12. Trayanova, N.A.; Chang, K.C. How computer simulations of the human heart can improve anti-arrhythmia therapy. J. Physiol. 2016, 594, 2483–2502. [Google Scholar] [CrossRef] [PubMed]
  13. Su, S.; Shih, C.L. Modeling an emergency medical services system using computer simulation. Int. J. Med. Inform. 2003, 72, 57–72. [Google Scholar] [CrossRef] [PubMed]
  14. Bruppacher, H.R.; Alam, S.K.; LeBlanc, V.R.; Naik, V.N.; Savoldelli, G.L.; Mazer, C.D.; Kurrek, M.M.; Joo, H.S. Simulation-based training improves physicians’ performance in patient care in high-stakes clinical setting of cardiac surgery. Anesthesiology 2010, 112, 985–992. [Google Scholar] [CrossRef] [PubMed]
  15. El Faquir, N.; Ren, B.; Van Mieghem, N.M.; Bosmans, J.; De Jaegere, P.P. Patient-specific computer modelling–its role in the planning of transcatheter aortic valve implantation. Neth. Heart J. 2017, 25, 100–105. [Google Scholar] [CrossRef] [PubMed]
  16. de Jaegere, P.; Rocatello, G.; Prendergast, B.D.; de Backer, O.; Van Mieghem, N.M.; Rajani, R. Patient-specific computer simulation for transcatheter cardiac interventions: What a clinician needs to know. Heart 2019, 105, s21–s27. [Google Scholar] [CrossRef] [PubMed]
  17. Højager, A.; Schoos, M.M.; Tingsgaard, P.K.; Bock, T.G.; Homøe, P. Prevalence of silent atrial fibrillation and cardiovascular disease in patients with obstructive sleep apnea. Sleep Med. 2022, 100, 534–541. [Google Scholar] [CrossRef] [PubMed]
  18. Magnani, J.W.; Rienstra, M.; Lin, H.; Sinner, M.F.; Lubitz, S.A.; McManus, D.D.; Dupuis, J.; Ellinor, P.T.; Benjamin, E.J. Atrial fibrillation: Current knowledge and future directions in epidemiology and genomics. Circulation 2011, 124, 1982–1993. [Google Scholar] [CrossRef] [PubMed]
  19. Naser, N.; Kulic, M.; Dilic, M.; Dzubur, A.; Durak, A.; Pepic, E.; Smajic, E.; Kusljugic, Z. The cumulative incidence of stroke, myocardial infarction, heart failure and sudden cardiac death in patients with atrial fibrillation. Med. Arch. 2017, 71, 316–319. [Google Scholar] [CrossRef] [PubMed]
  20. Moreno-Ruiz, L.A.; Rodríguez-Piña, H.; Martínez-Flores, J.E. Fibrilación auricular evaluación y tratamiento. Rev. Med. Inst. Mex. Seguro Soc. 2012, 50, 273–284. [Google Scholar]
  21. Rojas-Durán, A.M.; Sáenz-Morales, O.A.; Garay-Fernández, M.; Vergara-Vela, E. Evaluación del tratamiento de la fibrilación auricular valvular y no valvular y su relación con eventos adversos en pacientes hospitalizados en el servicio de urgencias de un hospital de tercer nivel. Rev. Colomb. Cardiol. 2020, 27, 529–537. [Google Scholar] [CrossRef]
  22. Lara-Vaca, S.; Cordero-Cabra, A.; Martinez-Flores, E.; Iturralde-Torres, P. The Mexican Registry of Atrial Fibrillation (ReMeFa). Gac. Med. Mex. 2014, 150, 48–59. [Google Scholar] [PubMed]
  23. Rodríguez-Reyes, H.; Laguna-Muñoz, C.I.; Gallegos de Luna, C.F.; de los Ríos-Ibarra, M.O.; Salas-Pacheco, J.L.; Leyva-Pons, J.L.; Muñoz-Gutiérrez, L.M.; Vargas-Hernandez, A.; Rodríguez-Muñoz, K.M.; Barragán-Luna, J.; et al. Fibrilación auricular en población mexicana: Diferencias en presentación, comorbilidades y factores de riesgo entre hombres y mujeres. Arch. Cardiol. Mex. 2022, 92, 349–357. [Google Scholar] [CrossRef] [PubMed]
  24. Prystowsky, E.N.; Padanilam, B.J.; Fogel, R.I. Treatment of atrial fibrillation. J. Am. Med. Assoc. 2015, 314, 278–288. [Google Scholar] [CrossRef] [PubMed]
  25. Reiffel, J.A. Oral anticoagulation and antiarrhythmic drug therapy for atrial fibrillation. J. Innov. Card. Rhythm. Manag. 2018, 9, 3446. [Google Scholar] [CrossRef] [PubMed]
  26. Hachem, A.H.; Marine, J.E.; Tahboub, H.A.; Kamdar, S.; Kanjwal, S.; Soni, R.; Kanjwal, K. Radiofrequency ablation versus cryoablation in the treatment of paroxysmal atrial fibrillation: A meta-analysis. Cardiol. Res. Pract. 2018, 2018, 6276241. [Google Scholar] [CrossRef]
  27. Rottner, L.; Bellmann, B.; Lin, T.; Reissmann, B.; Tönnis, T.; Schleberger, R.; Nies, M.; Jungen, C.; Dinshaw, L.; Klatt, N.; et al. Catheter ablation of atrial fibrillation: State of the art and future perspectives. Cardiol. Ther. 2020, 9, 45–58. [Google Scholar] [CrossRef]
  28. Khargi, K.; Hutten, B.A.; Lemke, B.; Deneke, T. Surgical treatment of atrial fibrillation; a systematic review. Eur. J. Cardiothorac. 2005, 27, 258–265. [Google Scholar] [CrossRef] [PubMed]
  29. Tomaiko, E.; Su, W.W. Comparing radiofrequency and cryoballoon technology for the ablation of atrial fibrillation. Curr. Opin. Cardiol. 2019, 34, 1–5. [Google Scholar] [CrossRef] [PubMed]
  30. Shi, L.B.; Rossvoll, O.; Tande, P.; Schuster, P.; Solheim, E.; Chen, J. Cryoballoon vs. radiofrequency catheter ablation: Insights from NOrwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study). Europace 2022, 24, 226–233. [Google Scholar] [CrossRef]
  31. Kotadia, I.D.; Williams, S.E.; O’Neill, M. High-power, short-duration radiofrequency ablation for the treatment of AF. Arrhythm. Electrophysiol. Rev. 2019, 8, 265–272. [Google Scholar] [CrossRef]
  32. Habibi, M.; Berger, R.D.; Calkins, H. Radiofrequency ablation: Technological trends, challenges, and opportunities. Europace 2021, 23, 511–519. [Google Scholar] [CrossRef]
  33. Tao, T.; Zheng, J.; Xu, H. An abnormal left ventricular-atrial perforation after radiofrequency catheter ablation: A case report. J. Cardiothorac. Surg. 2019, 14, 185. [Google Scholar] [CrossRef] [PubMed]
  34. Zhao, Q.; Li, L.; Liu, N.; Zhang, M.; Wu, K.; Ruan, Y.; Bai, R.; Du, X.; Dong, J.; Ma, C. Early versus delayed removal of the pericardial drain in patients with cardiac tamponade complicating radiofrequency ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 2020, 31, 597–603. [Google Scholar] [CrossRef]
  35. Schoene, K.; Sepehri-Shamloo, A.; Sommer, P.; Jahnke, C.; Paetsch, I.; Hindricks, G.; Arya, A. Natural course of acquired pulmonary vein stenosis after radiofrequency ablation for atrial fibrillation-Is routine follow-up imaging indicated or not? J. Cardiovasc. Electrophysiol. 2019, 30, 1786–1791. [Google Scholar] [CrossRef]
  36. Liu, X.H.; Gao, X.F.; Jin, C.L.; Chen, C.F.; Chen, B.; Xu, Y.Z. Cryoballoon versus radiofrequency ablation for persistent atrial fibrillation: A systematic review and meta-analysis. Kardiol. Pol. 2020, 78, 20–29. [Google Scholar] [CrossRef] [PubMed]
  37. Kuck, K.H.; Brugada, J.; Fürnkranz, A.; Metzner, A.; Ouyang, F.; Chun, J.; Elvan, A. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N. Engl. J. Med. 2016, 374, 2235–2245. [Google Scholar] [CrossRef]
  38. Andrade, J.G.; Khairy, P.; Dubuc, M. Catheter cryoablation: Biology and clinical uses. Circ. Arrhythm. Electrophysiol. 2013, 6, 218–227. [Google Scholar] [CrossRef] [PubMed]
  39. Andrade, J.G.; Wazni, O.M.; Kuniss, M.; Hawkins, N.M.; Deyell, M.W.; Chierchia, G.B.; Nissen, S.; Verma, A.; Wells, G.A.; Turgeon, R.D. Cryoballoon ablation as initial treatment for atrial fibrillation: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2021, 78, 914–930. [Google Scholar] [CrossRef] [PubMed]
  40. Jin, E.S.; Wang, P.J. Cryoballoon ablation for atrial fibrillation: A comprehensive review and practice guide. Korean Circ. J. 2018, 48, 114–123. [Google Scholar] [CrossRef]
  41. Andrade, J.G. Cryoablation for atrial fibrillation. Heart Rhythm O2 2020, 1, 44–58. [Google Scholar] [CrossRef]
  42. Tokuda, M.; Yamashita, S.; Sato, H.; Oseto, H.; Ikewaki, H.; Yokoyama, M.; Isogai, R.; Tokutake, K.; Yokoyama, K.; Kato, M.; et al. Long-term course of phrenic nerve injury after cryoballoon ablation of atrial fibrillation. Sci. Rep. 2021, 11, 6226. [Google Scholar] [CrossRef] [PubMed]
  43. Molenaar, M.M.; Timmermans, C.C.; Hesselink, T.; Scholten, M.F.; ter Bekke, R.M.; Luermans, J.G.; Brusse-Keizer, M.; Kraaier, K.; ten Haken, B.; Grandjean, J.G.; et al. Shorter cryoballoon applications times do effect efficacy but result in less phrenic nerve injury: Results of the randomized 123 study. Pacing Clin. Electrophysiol. 2019, 42, 508–514. [Google Scholar] [CrossRef] [PubMed]
  44. Anwar, O.; Gunawardene, M.A.; Dickow, J.; Scherschel, K.; Jungen, C.; Münkler, P.; Eickholt, C.; Willems, S.; Gessler, N.; Meyer, C. Contemporary analysis of phrenic nerve injuries following cryoballoon-based pulmonary vein isolation: A single-centre experience with the systematic use of compound motor action potential monitoring. PLoS ONE 2020, 15, e0235132. [Google Scholar] [CrossRef] [PubMed]
  45. Ghosh, J.; Sepahpour, A.; Chan, K.H.; Singarayar, S.; McGuire, M.A. Immediate balloon deflation for prevention of persistent phrenic nerve palsy during pulmonary vein isolation by balloon cryoablation. Heart Rhythm. 2013, 10, 646–652. [Google Scholar] [CrossRef] [PubMed]
  46. Rieder, C.; Schwenke, M.; Pätz, T.; Georgii, J.; Ballhausen, H.; Schwen, L.O.; Haase, S.; Preusser, T. Evaluation of a numerical simulation for cryoablation–comparison with bench data, clinical kidney and lung cases. Int. J. Hyperth. 2020, 37, 1268–1278. [Google Scholar] [CrossRef] [PubMed]
  47. González-Suárez, A.; Pérez, J.J.; Irastorza, R.M.; D’Avila, A.; Berjano, E. Computer modeling of radiofrequency cardiac ablation: 30 years of bioengineering research. Comput. Methods Programs Biomed. 2022, 214, 106546. [Google Scholar] [CrossRef] [PubMed]
  48. Pérez, J.J.; D’Avila, A.; Aryana, A.; Trujillo, M.; Berjano, E. Can fat deposition after myocardial infarction alter the performance of RF catheter ablation of scar-related ventricular tachycardia?: Results from a computer modeling study. J. Cardiovasc. Electrophysiol. 2016, 27, 947–952. [Google Scholar] [CrossRef]
  49. González-Suárez, A.; Berjano, E.; Guerra, J.M.; Gerardo-Giorda, L. Computational modeling of open-irrigated electrodes for radiofrequency cardiac ablation including blood motion-saline flow interaction. PLoS ONE 2016, 11, e0150356. [Google Scholar] [CrossRef] [PubMed]
  50. Petras, A.; Leoni, M.; Guerra, J.M.; Gerardo-Giorda, L. A computational model of open-irrigated radiofrequency catheter ablation accounting for mechanical properties of the cardiac tissue. Int. J. Numer. Method. Biomed. Eng. 2019, 35, e3232. [Google Scholar] [CrossRef]
  51. Yan, S.; Gu, K.; Wu, X.; Wang, W. Computer simulation study on the effect of electrode–tissue contact force on thermal lesion size in cardiac radiofrequency ablation. Int. J. Hyperth. 2020, 37, 37–48. [Google Scholar] [CrossRef]
  52. Müssig, R.; Müssig, R.; Hörth, J. Cryoballoon model and simulation of catheter ablation for pulmonary vein isolation in atrial fibrillation. Curr. Dir. Biomed. Eng. 2018, 4, 473–475. [Google Scholar] [CrossRef]
  53. Getman, M.K.; Wissner, E.; Ranjan, R.; Lalonde, J.P. Relationship between time-to-isolation and freeze duration: Computational modeling of dosing for Arctic Front Advance and Arctic Front Advance Pro cryoballoons. J. Cardiovasc. Electrophysiol. 2019, 30, 2274–2282. [Google Scholar] [CrossRef] [PubMed]
  54. COMSOL Multiphysics. Introduction to Heat Transfer Module. Available online: https://doc.comsol.com/5.4/doc/com.comsol.help.heat/IntroductionToHeatTransferModule.pdf (accessed on 6 July 2024).
  55. Patel, T.; Li, C.; Raissi, F.; Kassab, G.S.; Gao, T.; Lee, L.C. Coupled thermal-hemodynamics computational modeling of cryoballoon ablation for pulmonary vein isolation. Comput. Biol. Med. 2023, 157, 106766. [Google Scholar] [CrossRef] [PubMed]
  56. Lenhardt, R.; Sessler, D.I. Estimation of mean body temperature from mean skin and core temperature. Anesthesiology 2006, 105, 1117–1121. [Google Scholar] [CrossRef] [PubMed]
  57. Elwassif, M.M.; Kong, Q.; Vazquez, M.; Bikson, M. Bio-heat transfer model of deep brain stimulation-induced temperature changes. J. Neural Eng. 2006, 3, 306–315. [Google Scholar] [CrossRef] [PubMed]
  58. Potenza, M.; Pisano, C.; Coppa, P.; Bovesecchi, G.; Corasaniti, S.; Barbero, F. Numerical simulations of temperature inside the heart tissues to evaluate the performances of cryoablative probe. Int. J. Heat. Mass. Transf. 2023, 146, 106877. [Google Scholar] [CrossRef]
  59. Pennes, H.H. Analysis of tissue and arterial blood temperatures in the resting human forearm. J. Appl. Physiol. 1948, 1, 93–122. [Google Scholar] [CrossRef] [PubMed]
  60. Shih, T.C.; Yuan, P.; Lin, W.L.; Kou, H.S. Analytical analysis of the Pennes bioheat transfer equation with sinusoidal heat flux condition on skin surface. Med. Eng. Phys. 2007, 29, 946–953. [Google Scholar] [CrossRef] [PubMed]
  61. Pérez, J.J.; González-Suárez, A.; Berjano, E. Numerical analysis of thermal impact of intramyocardial capillary blood flow during radiofrequency cardiac ablation. Int. J. Hyperth. 2017, 34, 243–249. [Google Scholar] [CrossRef]
  62. Kozlov, M.; Horner, M.; Kainz, W.; Weiskopf, N.; Möller, H.E. Modeling radio-frequency energy-induced heating due to the presence of transcranial electric stimulation setup at 3T. Magn. Reson. Mater. Phys. Biol. Med. 2020, 33, 793–807. [Google Scholar] [CrossRef]
  63. Townsley, M.I. Structure and composition of pulmonary arteries, capillaries and veins. Compr. Physiol. 2012, 2, 675–709. [Google Scholar] [PubMed]
  64. Su, W.; Orme, G.J.; Hoyt, R.; Baker, J.; Compton, S.; Fellows, C.; Harding, J.; Svinarich, J.T.; Kowalski, M.; Piedad, B.; et al. Retrospective review of Arctic Front Advance Cryoballoon Ablation: A multicenter examination of second-generation cryoballoon (RADICOOL trial). J. Interv. Card. Electrophysiol. 2018, 51, 199–204. [Google Scholar] [CrossRef] [PubMed]
  65. Kim, Y.H.; Marom, E.M.; Herndon, J.E.; McAdams, H.P. Pulmonary vein diameter, cross-sectional area, and shape: CT analysis. Radiology 2015, 235, 43–49. [Google Scholar] [CrossRef] [PubMed]
  66. Garan, A.; Al-Ahmad, A.; Mihalik, T.; Cartier, C.; Capuano, L.; Holtan, D.; Song, C.; Homoud, M.K.; Link, M.S.; Mark Estes III, N.A.; et al. Cryoablation of the pulmonary veins using a novel balloon catheter. J. Interv. Card. Electrophysiol. 2006, 15, 79–81. [Google Scholar] [CrossRef]
  67. Barnett, A.S.; Bahnson, T.D.; Piccini, J.P. Recent advances in lesion formation for catheter ablation of atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2016, 9, e003299. [Google Scholar] [CrossRef] [PubMed]
  68. Rothenborg, H.W. Cryoprotective properties of vasoconstriction. Cryobiology 1977, 14, 349–361. [Google Scholar] [CrossRef] [PubMed]
  69. Avitall, B.; Kalinski, A. Cryotherapy of cardiac arrhythmia: From basic science to the bedside. Heart Rhythm. 2015, 2, 2195–2203. [Google Scholar] [CrossRef] [PubMed]
  70. Coulombe, N.; Paulin, J.; Su, W. Improved in vivo performance of second-generation cryoballoon for pulmonary vein isolation. J. Cardiovasc. Electrophysiol. 2013, 24, 919–925. [Google Scholar] [CrossRef]
  71. Nie, Z.; Zhao, D.; Ren, Z.; Hou, C.R.; Su, X.; Deng, C.; Yao, Y.; Tang, K.; Li, Y.; Fu, H.; et al. Liquid nitrogen cryoballoon ablation system for paroxysmal atrial fibrillation: A multicenter, prospective, single-arm clinical trial. J. Am. Coll. Cardiol. Asia 2023, 3, 805–816. [Google Scholar]
  72. Abugattas, J.P.; de Asmundis, C.; Iacopino, S.; Salghetti, F.; Takarada, K.; Coutiño, H.E.; Ströker, E.; De Regibus, V.; de Greef, Y.; Brugada, P.; et al. Phrenic nerve injury during right inferior pulmonary vein ablation with the second-generation cryoballoon: Clinical, procedural, and anatomical characteristics. Europace 2018, 20, e156–e163. [Google Scholar] [CrossRef]
  73. Heeger, C.H.; Popescu, S.Ș.; Sohns, C.; Pott, A.; Metzner, A.; Inaba, O.; Straube, F.; Kuniss, M.; Aryana, A.; Miyazaki, S.; et al. Impact of cryoballoon application abortion due to phrenic nerve injury on reconnection rates: A YETI subgroup analysis. Europace 2023, 25, 374–381. [Google Scholar] [CrossRef] [PubMed]
  74. Sorguven, E.; Bozkurt, S.; Baldock, C. Computer simulations can replace in-vivo experiments for implantable medical devices. Phys. Eng. Sci. Med. 2021, 44, 1–5. [Google Scholar] [CrossRef] [PubMed]
  75. Burks, A.C.; Keim-Malpass, J. Health literacy and informed consent for clinical trials: A systematic review and implications for nurses. Nursing Res. Rev. 2019, 9, 31–40. [Google Scholar] [CrossRef]
  76. Pietrzykowski, T.; Smilowska, K. The reality of informed consent: Empirical studies on patient comprehension—Systematic review. Trials 2021, 22, 57. [Google Scholar] [CrossRef] [PubMed]
  77. Indrayan, A.; Mishra, A. The importance of small samples in medical research. J. Postgrad. Med. 2021, 67, 219–223. [Google Scholar] [CrossRef] [PubMed]
  78. Miyazaki, S.; Hasegawa, K.; Mukai, M.; Aoyama, D.; Nodera, M.; Shiomi, Y.; Tama, N.; Ikeda, H.; Ishida, K.; Uzui, H.; et al. The advantages and disadvantages of the novel fourth-generation cryoballoon as compared to the second-generation cryoballoon in the current short freeze strategy. J. Interv. Card. Electrophysiol. 2022, 63, 143–152. [Google Scholar] [CrossRef]
  79. Vennin, S. How modelling is transforming medicine. Phys. World 2020, 33, 41. [Google Scholar] [CrossRef]
Figure 1. Geometric model. (A) Frontal view and (B) back view.
Figure 1. Geometric model. (A) Frontal view and (B) back view.
Healthcare 12 01508 g001
Figure 2. Lesion cross-section area.
Figure 2. Lesion cross-section area.
Healthcare 12 01508 g002
Figure 3. Computational model for temperature distribution during cryotherapy.
Figure 3. Computational model for temperature distribution during cryotherapy.
Healthcare 12 01508 g003
Figure 4. Results of CBA simulation for five patients (AE) undergoing cryotherapy, including the highest distances from the cryoballoon to the vascular wall and to the outermost border of pulmonary tissue.
Figure 4. Results of CBA simulation for five patients (AE) undergoing cryotherapy, including the highest distances from the cryoballoon to the vascular wall and to the outermost border of pulmonary tissue.
Healthcare 12 01508 g004
Table 1. Thermal and physiological properties of the materials used for simulation.
Table 1. Thermal and physiological properties of the materials used for simulation.
MaterialThermal
Conductivity
(W/mK)
Specific Heat
(J/kgK)
Tissue Density
(kg/m3)
Temperature
Blood0.5440001057310.15
Vascular wall1.336001200310
Polyurethane0.0215001110198.15
Pulmonary tissue0.0329631000311
Table 2. Time in seconds and temperature records for patients undergoing CBA therapy.
Table 2. Time in seconds and temperature records for patients undergoing CBA therapy.
Patient 1Patient 2Patient 3Patient 4Patient 5
TZ (0 °C) = 10TZ (0 °C) = 8TZ (0 °C) = 12TZ (0 °C) = 12TZ (0 °C) = 13
TI (−30 °C) = 23TI (−30 °C) = 29TI (−30 °C) = 36TI (−30 °C) = 30TI (−30 °C) = 31
TM (−60 °C) = 32TM (−42 °C) = 33TM (−41 °C) = 42TM (−63 °C) = 34TM (−43 °C) = 35
TT = 240TT = 240TT = 240TT = 240TT = 240
Table 3. Simulation parameters for pulmonary veins.
Table 3. Simulation parameters for pulmonary veins.
Pulmonary VeinOstium Diameter (mm)Vascular Wall Thickness (mm)
Right superior182.7
Right inferior121.8
Left superior192.8
Left inferior131.9
Table 4. Results of computer simulation for lesion formation and penetration of temperature through tissue depths after CBA.
Table 4. Results of computer simulation for lesion formation and penetration of temperature through tissue depths after CBA.
Maximum Freezing Temperatures (°C)Distance between Cryoballoon
and Vascular Wall (mm)
Lesion Depth (mm)Lesion Area
(mm2)
−603.884.2877.28
−423.843.2458.50
−414.073.0054.17
−613.953.9671.50
−434.093.0855.61
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rivera, S.I.; Bernal, C.P.; Martínez-Peláez, R.; Robledo-Nolasco, R.; De León-Larios, G.; Félix, V.G.; Ostos, R.; Maestre, G.E.; Melgarejo, J.D.; Mena, L.J. Computer Simulation of Catheter Cryoablation for Pulmonary Vein Isolation. Healthcare 2024, 12, 1508. https://doi.org/10.3390/healthcare12151508

AMA Style

Rivera SI, Bernal CP, Martínez-Peláez R, Robledo-Nolasco R, De León-Larios G, Félix VG, Ostos R, Maestre GE, Melgarejo JD, Mena LJ. Computer Simulation of Catheter Cryoablation for Pulmonary Vein Isolation. Healthcare. 2024; 12(15):1508. https://doi.org/10.3390/healthcare12151508

Chicago/Turabian Style

Rivera, Solange I., Clara P. Bernal, Rafael Martínez-Peláez, Rogelio Robledo-Nolasco, Gerardo De León-Larios, Vanessa G. Félix, Rodolfo Ostos, Gladys E. Maestre, Jesús D. Melgarejo, and Luis J. Mena. 2024. "Computer Simulation of Catheter Cryoablation for Pulmonary Vein Isolation" Healthcare 12, no. 15: 1508. https://doi.org/10.3390/healthcare12151508

APA Style

Rivera, S. I., Bernal, C. P., Martínez-Peláez, R., Robledo-Nolasco, R., De León-Larios, G., Félix, V. G., Ostos, R., Maestre, G. E., Melgarejo, J. D., & Mena, L. J. (2024). Computer Simulation of Catheter Cryoablation for Pulmonary Vein Isolation. Healthcare, 12(15), 1508. https://doi.org/10.3390/healthcare12151508

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop